Navigation Links
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Date:9/10/2013

TARRYTOWN, N.Y., Sept. 10, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of Robert E. Landry as Senior Vice President, Finance.  Mr. Landry will also assume the position of Chief Financial Officer of Regeneron on October 1.  After 18 years as CFO, Murray A. Goldberg will transition to a new role as Senior Vice President, Administration in anticipation of his retirement at the end of 2014.

Mr. Landry brings over two decades of varied financial and operating experience in the global pharmaceutical industry, most recently as Senior Vice President and Treasurer of Pfizer, Inc.  He will report to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  Mr. Landry will have responsibility for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit.  In his new role, Mr. Goldberg will continue to have responsibility for Alliance Management and various administrative functions.

"Murray has been an integral member of the Regeneron senior management team for close to two decades and his contribution to our success as we grew from a development stage biotechnology company to one of the largest biotechnology companies in the world has been invaluable.  We are extremely fortunate that Murray will stay at Regeneron through 2014 to help us with the transition to a new CFO," said Dr. Schleifer.  "Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth.  We look forward to the valuable perspective he will bring, as we continue to expand our operations in the U.S. and globally."

"I am pleased to be able to join an organization that is known for its deep commitment to science and to bringing life changing medicines to patients," said Robert Landry.  "I am excited about this opportunity and look forward to working with the talented Regeneron management team."

Prior to serving as Senior Vice President and Treasurer of Pfizer, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth and Pfizer including Senior Vice President – Finance, Pfizer's Diversified Businesses, Treasurer of Wyeth, Director of Sales and Marketing and Chief Financial Officer for Wyeth Pharmaceuticals' Australian and New Zealand affiliates, and various other assignments in both the pharmaceuticals business and the parent company.  Mr. Landry joined Wyeth after spending two years as an auditor with PricewaterhouseCoopers LLP.  He holds a B.B.A in Accounting from the University of Notre Dame.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
4. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
7. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
8. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
9. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... Massachusetts , May 26, 2016 ... (NGS) has matured into an essential life science tool ... and development applications. BCC Research reveals in its new ... a second growth phase, one powered by a range ... fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web themed ... the style of their project," said Christina Austin - CEO of Pixel Film Studios. ... created exclusively for use in Final Cut Pro X. Pixel Film Studios’ minimalistic titles ...
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search ... Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at Ashbury ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by KSF ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of ... not surprising that bariatric surgery has received increased attention in recent years, as an ... when it comes to weight loss, most people are familiar with the basic requirements ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... W.S. ... products, announced today that it has been recognized as one of the best small ... Badger was named as one of nine small businesses providing progressive benefits to new ...
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
Breaking Medicine News(10 mins):